CY1121204T1 - Συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη για διαταραχες που προκαλουνται απο την ige - Google Patents

Συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη για διαταραχες που προκαλουνται απο την ige

Info

Publication number
CY1121204T1
CY1121204T1 CY20191100107T CY191100107T CY1121204T1 CY 1121204 T1 CY1121204 T1 CY 1121204T1 CY 20191100107 T CY20191100107 T CY 20191100107T CY 191100107 T CY191100107 T CY 191100107T CY 1121204 T1 CY1121204 T1 CY 1121204T1
Authority
CY
Cyprus
Prior art keywords
ige
compositions
treatment
methods
disorders caused
Prior art date
Application number
CY20191100107T
Other languages
English (en)
Inventor
John R. Desjarlais
Seung Y. Chu
Holly M. Horton
Original Assignee
Xencor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor, Inc. filed Critical Xencor, Inc.
Publication of CY1121204T1 publication Critical patent/CY1121204T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η παρούσα περιγραφή αφορά ανοσοσφαιρίνες που δεσμεύουν την IgE και τον FcγRIIb με υψηλή συγγένεια, καθώς και συνθέσεις που περιλαμβάνουν τις εν λόγω ανοσοσφαιρίνες με δυνατότητα αναστολής κυττάρων που εκφράζουν αγκυρωμένη σε μεμβράνη IgE. Τέτοιες συνθέσεις είναι χρήσιμες για τη θεραπευτική αγωγή για διαταραχές που προκαλούνται από την IgE, συμπεριλαμβανομένων αλλεργιών και άσθματος.
CY20191100107T 2008-09-17 2019-01-24 Συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη για διαταραχες που προκαλουνται απο την ige CY1121204T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9781908P 2008-09-17 2008-09-17
EP14188102.9A EP2853545B8 (en) 2008-09-17 2009-09-17 Antibody specific for IgE
PCT/US2009/057366 WO2010033736A1 (en) 2008-09-17 2009-09-17 Novel compositons and methods for treating ige-mediated disorders
EP09792678.6A EP2331578B1 (en) 2008-09-17 2009-09-17 Novel compositions and methods for treating ige-mediated disorders
EP13185738.5A EP2703415B1 (en) 2008-09-17 2009-09-17 Compositions and methods for treating IgE-mediated disorders

Publications (1)

Publication Number Publication Date
CY1121204T1 true CY1121204T1 (el) 2020-05-29

Family

ID=41510648

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100825T CY1118002T1 (el) 2008-09-17 2016-08-22 ΑΝΤΙΣΩΜΑ ΕΙΔΙΚΟ ΓΙΑ IgE
CY20191100107T CY1121204T1 (el) 2008-09-17 2019-01-24 Συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη για διαταραχες που προκαλουνται απο την ige

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100825T CY1118002T1 (el) 2008-09-17 2016-08-22 ΑΝΤΙΣΩΜΑ ΕΙΔΙΚΟ ΓΙΑ IgE

Country Status (20)

Country Link
US (9) US8435517B2 (el)
EP (7) EP3581588B1 (el)
JP (2) JP5785493B2 (el)
KR (1) KR101783272B1 (el)
CN (2) CN102292353B (el)
AU (1) AU2009293143C1 (el)
BR (1) BRPI0918670B8 (el)
CA (1) CA2736511C (el)
CY (2) CY1118002T1 (el)
DK (3) DK2796469T3 (el)
ES (6) ES2708842T3 (el)
HR (1) HRP20182135T1 (el)
HU (2) HUE042901T2 (el)
LT (2) LT3190128T (el)
PL (2) PL2853545T3 (el)
PT (2) PT2853545T (el)
SI (2) SI3190128T1 (el)
SM (1) SMT201600288B (el)
TR (1) TR201821216T4 (el)
WO (1) WO2010033736A1 (el)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) * 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
ES2397441T5 (es) 2006-02-13 2022-09-14 Daiichi Sankyo Co Ltd Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CN101479381B (zh) 2006-03-31 2015-04-29 中外制药株式会社 调控抗体血液动力学的方法
EP3392273A1 (en) * 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
CN103251948A (zh) 2008-04-11 2013-08-21 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
US20170247470A9 (en) * 2008-09-17 2017-08-31 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP3581588B1 (en) 2008-09-17 2022-06-15 Xencor, Inc. Novel compositions and methods for treating ige-mediated disorders
US9187568B2 (en) * 2009-05-07 2015-11-17 Stallergenes S.A. Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011097527A2 (en) * 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US9187552B2 (en) 2010-05-27 2015-11-17 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
EP2591097A1 (en) 2010-07-06 2013-05-15 Novartis AG Norovirus derived immunogenic compositions and methods
CN105585630B (zh) 2010-07-29 2020-09-15 Xencor公司 具有修改的等电点的抗体
US10017762B2 (en) * 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
CN107973851A (zh) 2010-11-30 2018-05-01 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
EP3431993A1 (en) * 2010-12-20 2019-01-23 The Rockefeller University Modulating agonistic tnfr antibodies
EP2673635A4 (en) * 2011-02-07 2015-08-12 Neotope Biosciences Ltd IMMUNOTHERAPY THROUGH APOE
AU2012258907A1 (en) 2011-05-25 2013-11-07 Merck Sharp & Dohme Corp. Method for preparing Fc-containing polypeptides having improved properties
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EA201590247A1 (ru) 2012-07-19 2015-10-30 Алетиа Байотерапьютикс Инк. Антитела к siglec-15
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
TWI717591B (zh) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
MX2015005874A (es) 2012-11-09 2015-09-10 Pfizer Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
GB201308658D0 (en) * 2013-05-14 2013-06-26 Isis Innovation Antibodies
SG10201909806SA (en) 2013-11-04 2019-11-28 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
WO2015073580A1 (en) 2013-11-13 2015-05-21 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
WO2015153678A2 (en) * 2014-04-02 2015-10-08 Tunitas Therapeutics, Inc. Epsigam fusion protein
AU2015292326A1 (en) * 2014-07-24 2017-02-23 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
EA037065B1 (ru) 2014-11-26 2021-02-01 Ксенкор, Инк. Гетеродимерные антитела, связывающие cd3 и cd38
BR112017011092A2 (pt) 2014-11-26 2017-12-26 Xencor Inc anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
MA41294A (fr) 2014-12-19 2017-11-08 Chugai Pharmaceutical Co Ltd Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20230054508A (ko) 2016-06-14 2023-04-24 젠코어 인코포레이티드 이중특이적 체크포인트 억제제 항체
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
RU2766112C2 (ru) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Композиция для профилактики или лечения связанных с il-8 заболеваний
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN110214147A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15Rα异源二聚体FC-融合蛋白
CA3045797A1 (en) * 2016-12-02 2018-06-07 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies
JP2020529832A (ja) 2017-06-30 2020-10-15 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
CN110945028B (zh) 2017-07-10 2023-09-08 国际药物发展生物技术公司 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
PE20210043A1 (es) 2018-01-08 2021-01-08 Gi Innovation Inc Dominio extracelular de subunidad alfa del receptor fc de ige, composicion farmaceutica que comprende el mismo y metodo para producir el mismo
TW201930343A (zh) 2018-01-08 2019-08-01 南韓商普羅根有限公司 包含IgE受體之重組型胞外區域的藥學組成物
BR112020013818A2 (pt) 2018-01-12 2020-12-01 Gi Innovation, Inc. composição compreendendo probióticos e polipeptídeo com afinidade de ligação para ige e uso dos mesmos
MX2020008291A (es) * 2018-02-09 2020-09-25 Genentech Inc Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos.
KR20200132938A (ko) 2018-03-15 2020-11-25 추가이 세이야쿠 가부시키가이샤 지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
WO2019234576A1 (en) 2018-06-03 2019-12-12 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
WO2020172072A1 (en) * 2019-02-21 2020-08-27 The General Hospital Corporation Glycoengineering immunoglobulin e
KR20210134725A (ko) 2019-03-01 2021-11-10 젠코어 인코포레이티드 Enpp3과 cd3에 결합하는 이종이량체 항체
JP2022539684A (ja) 2019-07-08 2022-09-13 ジーアイ イノベーション， インコーポレイテッド 高シアル酸含量を有し、ＩｇＥ Ｆｃ受容体のアルファサブユニットの細胞外ドメインを含むポリペプチド二量体及び同ポリペプチド二量体を含む医薬組成物
CN110836935B (zh) * 2019-11-25 2022-01-28 重庆柳江医药科技有限公司 测定甲磺司特原料药中3种基因毒性杂质的方法
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
IL301701A (en) 2020-12-18 2023-05-01 Lamkap Bio Beta Ag Bispecific antibodies against CEACAM5 and CD47
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
MX2023010457A (es) 2021-03-09 2023-09-14 Gi Innovation Inc Formulacion de proteina de fusion que incluye el dominio extracelular de la subunidad alfa del receptor fc de ige.
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
WO2024003376A1 (en) 2022-07-01 2024-01-04 Alk-Abelló A/S Displacers of ige-fceri

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US459004A (en) 1891-09-08 Box for steaming cops
US2228904A (en) 1939-05-10 1941-01-14 Bjorkman Hugo Leonard Wrench
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5614611A (en) 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5342924A (en) 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5084468A (en) 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US6699472B2 (en) * 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US7118743B2 (en) 1998-11-17 2006-10-10 Tanox, Inc. Bispecific molecules cross-linking ITIM and ITAM for therapy
DK2270149T3 (en) 1999-04-09 2016-05-09 Kyowa Hakko Kirin Co Ltd PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE.
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
EP1170692B1 (en) 2000-07-07 2009-03-25 AMPHENOL-TUCHEL ELECTRONICS GmbH A smart-card reader
WO2002005146A2 (en) 2000-07-10 2002-01-17 Xencor, Inc. Method for disigning protein libraries with altered immunogenicity
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
AU2001294175A1 (en) 2000-10-06 2002-04-22 Kyowa Hakko Kogyo Co. Ltd. Method of purifying antibody
EP1383800A4 (en) 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
JP2006513139A (ja) 2002-07-03 2006-04-20 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療薬の全身性送達のための中央部気道投与
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1581904A2 (en) 2003-01-08 2005-10-05 Xencor, Inc. Novel proteins with altered immunogenicity
CA2513113A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
JP2006516408A (ja) 2003-02-01 2006-07-06 タノックス インコーポレーテッド 高親和性抗体の生成方法
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
WO2006048781A2 (en) 2004-05-20 2006-05-11 St. Mary's Hospital Nhs Trust IgE-RETARGETING, FUNCTION-ALTERING MOLECULES (ERFAM) FOR TREATMENT OF ALLERGIC DISEASES
EP1919950A1 (en) * 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
WO2006047350A2 (en) * 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US7301640B2 (en) 2004-12-21 2007-11-27 Honeywell International, Inc. System and method of condensation reduction in an electrical unit
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
ES2971647T3 (es) 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
GT200800034A (es) * 2007-04-02 2010-03-16 Anticuerpos anti-ige
EP3392273A1 (en) 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
DK2235059T3 (en) 2007-12-26 2015-03-30 Xencor Inc FC-VERSIONS OF MODIFIED BINDING TO FcRn
EP2280997A2 (en) 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
EP3581588B1 (en) 2008-09-17 2022-06-15 Xencor, Inc. Novel compositions and methods for treating ige-mediated disorders
US20170247470A9 (en) * 2008-09-17 2017-08-31 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
US20110189178A1 (en) 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
US9146069B2 (en) 2012-05-22 2015-09-29 Haptech, Inc. Method and apparatus for firearm recoil simulation
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Also Published As

Publication number Publication date
JP2015187185A (ja) 2015-10-29
PT3190128T (pt) 2019-02-07
ES2742419T3 (es) 2020-02-14
PL3190128T3 (pl) 2019-06-28
US20100080814A1 (en) 2010-04-01
EP2796469B1 (en) 2019-05-08
EP3190128A1 (en) 2017-07-12
KR101783272B1 (ko) 2017-09-29
CA2736511C (en) 2017-06-13
KR20110061616A (ko) 2011-06-09
US8435517B2 (en) 2013-05-07
SI2853545T1 (sl) 2016-10-28
US20130203967A1 (en) 2013-08-08
US9062117B2 (en) 2015-06-23
LT2853545T (lt) 2016-09-26
US20150139985A1 (en) 2015-05-21
US20170335013A1 (en) 2017-11-23
US20200332024A1 (en) 2020-10-22
SMT201600288B (it) 2016-11-10
US9540451B2 (en) 2017-01-10
PL2853545T3 (pl) 2016-12-30
AU2009293143B2 (en) 2015-04-09
EP2331578B1 (en) 2014-06-04
SI3190128T1 (sl) 2019-04-30
EP2853545B8 (en) 2023-04-05
WO2010033736A1 (en) 2010-03-25
US11566080B2 (en) 2023-01-31
US9617348B2 (en) 2017-04-11
CN104961830A (zh) 2015-10-07
CN102292353B (zh) 2015-04-29
JP6178819B2 (ja) 2017-08-09
DK3190128T3 (en) 2019-01-28
US20130203966A1 (en) 2013-08-08
EP2796469A2 (en) 2014-10-29
TR201821216T4 (tr) 2019-01-21
EP2331578A1 (en) 2011-06-15
ES2727677T3 (es) 2019-10-17
EP3190128B1 (en) 2018-11-14
CN102292353A (zh) 2011-12-21
JP5785493B2 (ja) 2015-09-30
BRPI0918670B1 (pt) 2020-09-24
EP4155323A1 (en) 2023-03-29
ES2589852T3 (es) 2016-11-16
EP3581588A1 (en) 2019-12-18
CY1118002T1 (el) 2017-05-17
EP2853545B1 (en) 2016-05-25
US20230272114A1 (en) 2023-08-31
EP2703415A1 (en) 2014-03-05
EP2796469A3 (en) 2014-11-05
US20150093379A1 (en) 2015-04-02
US9221916B2 (en) 2015-12-29
HRP20182135T1 (hr) 2019-03-22
US20130177553A1 (en) 2013-07-11
BRPI0918670B8 (pt) 2021-05-25
US9266966B2 (en) 2016-02-23
HUE029341T2 (en) 2017-02-28
HUE042901T2 (hu) 2019-07-29
DK2796469T3 (da) 2019-08-12
PT2853545T (pt) 2016-08-26
ES2708842T3 (es) 2019-04-11
CA2736511A1 (en) 2010-03-25
CN104961830B (zh) 2018-09-07
AU2009293143C1 (en) 2015-07-23
BRPI0918670A2 (pt) 2015-12-01
DK2853545T3 (en) 2016-08-29
ES2499031T3 (es) 2014-09-26
AU2009293143A1 (en) 2010-03-25
EP2703415B1 (en) 2019-03-06
LT3190128T (lt) 2019-01-10
JP2012503007A (ja) 2012-02-02
ES2927192T3 (es) 2022-11-03
EP2853545A1 (en) 2015-04-01
EP3581588B1 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
CY1121204T1 (el) Συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη για διαταραχες που προκαλουνται απο την ige
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1120638T1 (el) Αναστολεις τυροσινικης κινασης πυριμιδινυλιου
CY1122646T1 (el) Δικυκλικες ετεροαρυλ ενωσεις
CY1120556T1 (el) Δικυκλικα ετεροκυκλα ως αναστολεις fgfr
CY1123552T1 (el) Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas
CY1120887T1 (el) Αντισωματα που προσδενουν il-4 και/ή il-13 και οι χρησεις τους
CY1119173T1 (el) Νεα μορια αναστολεα jnk
CY1118923T1 (el) ΔΡΑΣΤΙΚΑ ΜΕΤΑΛΛΑΓΜΑΤΑ Fc ΑΝΤΙΣΩΜΑΤΟΣ ΑΝΘΕΚΤΙΚΑ ΣΕ ΠΡΩΤΕΑΣΕΣ
CY1119286T1 (el) Ανταγωνιστες των wnt και μεθοδοι αγωγης
CY1116578T1 (el) Αναστολεις της bromodomain και χρησεις αυτων
CY1119399T1 (el) Aντι-dkk-1 αντισωματα
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1118244T1 (el) Αντισωματα κατα της il-25
CL2008001673A1 (es) Dominio variable simple de la inmunoglobulina del receptor tipo 1 de la anti-interleucina 1 (il-1r1); acido nucleico que lo codifica; vector y celula huesped; metodo de produccion; antagonista de il-1r1 que lo comprende; composicion que comprende al antagonista; y uso del antagonista para tratar una condicion inflamatoria.
CY1121368T1 (el) Αντισωματα anti-asic1 και χρησεις αυτων
CL2013000322A1 (es) Compuestos derivados de piperidina sustituida; proceso de preparacion; composicion farmaceutica y su uso para producir un efecto antiproliferativo y/o proapoptotico.
EA201491215A1 (ru) Несиалированные противовоспалительные полипептиды
BR112012023015A2 (pt) imunoensaios para lenalidomida e talidomida
BR112012022513A2 (pt) derivados de piperidin-4-il azetidina como inibidores de jak1
TR201905072T4 (tr) Bitkilerde abiyotik gerilime karşı toleransın arttırılmasına yönelik yöntemler.